Spillane A J
Sydney Cancer Centre, Royal Prince Alfred Hospital, New South Wales, Australia.
ANZ J Surg. 2001 May;71(5):303-8. doi: 10.1046/j.1440-1622.2001.02109.x.
Retroperitoneal sarcoma (RPS) is considered a disease with poor prognosis partly because of the difficulty with diagnosis at an early stage. This review assesses the current best practice principles for RPS and finds evidence suggesting a better outlook for appropriately managed cases. Recommendations are made for improving diagnostic certainty before laparotomy and inappropriate transperitoneal biopsy occur.
A critical review of the English language literature was conducted using MEDLINE software and searching the terms 'retroperitoneal sarcoma' alone or in combination with 'prognosis', 'surgery' and 'adjuvant therapy'.
Retroperitoneal sarcoma is a rare disease but when appropriately managed the disease-free survival can be improved and may even approach that of extremity soft tissue sarcoma. One of the greatest barriers to improving outcome is the misinterpretation of clinical signs and an over-reliance on ultrasound diagnosis in pelvic presentations, or misinterpretation of clinical signs and/or computer tomography (CT) scans in abdominal masses. Physicians referring patients with a retroperitoneal mass should consider more frequently the less common differential diagnoses of an abdominopelvic mass including retroperitoneal sarcoma. This is especially true in circumstances where there is a circumscribed, predominantly solid tumour, with clinical or radiological signs of vascular or rectal displacement, ureteric obstruction and/or classic renal rotational displacement. The more frequent use of CT scans with intravenous and oral contrast with referral prior to inappropriate transperitoneal biopsy is recommended. In atypical cases where preoperative biopsy is necessary, extraperitoneal routes are preferable. Complete en bloc surgical excision at the first laparotomy is the treatment of choice in RPS. Macroscopic clearance may necessitate resection of adjacent viscera, neurovascular structures or abdominopelvic walls but, if achieved, may lead to long-term survival depending on individual tumour biology.
腹膜后肉瘤(RPS)被认为是一种预后较差的疾病,部分原因是早期诊断困难。本综述评估了RPS当前的最佳实践原则,并发现有证据表明,经过适当管理的病例预后较好。针对在剖腹手术和不适当的经腹活检之前提高诊断确定性提出了建议。
使用MEDLINE软件对英文文献进行批判性综述,搜索术语“腹膜后肉瘤”,单独或与“预后”、“手术”和“辅助治疗”组合搜索。
腹膜后肉瘤是一种罕见疾病,但经过适当管理,无病生存期可以改善,甚至可能接近肢体软组织肉瘤。改善预后的最大障碍之一是对临床体征的错误解读,以及在盆腔肿物表现中过度依赖超声诊断,或在腹部肿物中对临床体征和/或计算机断层扫描(CT)的错误解读。转诊腹膜后肿物患者的医生应更频繁地考虑腹盆腔肿物较少见的鉴别诊断,包括腹膜后肉瘤。在存在边界清晰、主要为实性肿瘤,伴有血管或直肠移位、输尿管梗阻和/或典型肾脏旋转移位的临床或放射学征象的情况下尤其如此。建议在不适当的经腹活检之前,更频繁地使用静脉和口服对比剂的CT扫描并转诊。在需要术前活检的非典型病例中,腹膜外途径更佳。首次剖腹手术时完整整块切除是RPS的首选治疗方法。肉眼下切除可能需要切除相邻的内脏、神经血管结构或腹盆腔壁,但如果能够实现,根据个体肿瘤生物学特性,可能会带来长期生存。